Clinical Trials Directory

Trials / Completed

CompletedNCT01456715

Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
418 (actual)
Sponsor
Laval University · Academic / Other
Sex
Female
Age
12 Years – 14 Years
Healthy volunteers
Accepted

Summary

Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: * The immunogenicity and safety of Gardasil and Twinrix when co-administered. * The immunogenicity and safety of Cervarix when administered to subjects previously vaccinated with Gardasil. The main objective of the first phase of this clinical trial was: • To assess and compare the immunogenicity of Gardasil and Twinrix Junior when co-administered or administered at one month interval according to a 0, 6 month schedule to 9-10 year-old girls. The main objective of the seconde phase of this clinical trial is: • To determine the effect of a booster dose of Gardasil or Cervarix on HPV antibodies when given 42 months post-vaccination of 9-10 year-old girls with two doses of Gardasil. Study Design \& Duration: Experimental Design: Blind for the third HPV vaccine dose, randomized, single centre study with two treatment groups. Duration of the study: Participants will be followed for the duration of 10 years post-primary vaccination. Number of Centres: One Center.

Conditions

Interventions

TypeNameDescription
BIOLOGICALGardasil vaccine, Immunogenicity, Booster dose.Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
BIOLOGICALCervarix Vaccine, Immunogenicity, Booster Dose.Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.

Timeline

Start date
2008-09-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2011-10-21
Last updated
2020-03-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01456715. Inclusion in this directory is not an endorsement.